



### ANRS 0629s DEMELE-JEV

(Information for participants)

# Title Diagnostics and surveillance of acute meningo-encephalitis among children in Cambodia with a focus on Japanese Encephalitis Virus

Headings	Content	
In a nutshell	Saphonn Vonthanak & Audrey Dubot-Pérès	
The project (250 words max)	Structure/teams:  GHMI-Laboratoire de Génétique Humaine des Maladies Infectieuses Inserm UMR 1138, Höpital Necker-Enfants Malades, Paris, France. SESSTIM-Santé Épidémiologie et Systèmes de Soins, Technologies et Marseille, France. UVE: Unité des Virus Emergents, Inserm 1207 Aix-Marseille Université, France. UHS-University of Health Sciences, Phnom Penh, Cambodia. MMMI-Laboratoire de Modélisation Mathématique des Maladies Infectieuses Institut Pasteur de Paris, France. Institut Pasteur de Cambodia Hôpitalx Kantha Bopha, Phnom Penh, Cambodia Hôpitalx Kantha Bopha, Siem Reap, Cambodia. Hôpital Kantha Bopha, Siem Reap, Cambodia. CDC-Communicable Disease Control Department, Phnom Penh, Cambodia Start date/End date provisional 3th end 2025/3th end 2028 Number of participants: 2000 Status: Enrolment in progress. First enrolled on November 20, 2025. Pathology: Japanese encephalitis Sponsor: Inserm-ANRS MIE Funded by the AAP "Emergences PRFI" (ANRS-MIE) 2023/2024 & by the French Ministry for Europe and Foreign Affairs.  DEMELE-JEV is a prospective observational paediatric cohort, combining both cross-sectional and longitudinal designs, conducted in Cambodia. The primary aim of the study is to quantify the clinical burden of Japanese Encephalitis (JE) and to investigate the asymptomatic circulation of JEV among Cambodian children. The study focuses on two groups: children without fever at recruitment and children hospitalized with febrile neurological syndrome (FNS). Secondary objectives include estimating anti-JEV seropositivity rates, identifying individual risk factors and living conditions associated with JEV infection, characterizing clinical and biological profiles linked to disease severity, and evaluating the role of interferon (IFN) response deficiencies in severe JEV cases.	
Latest news (if applicable)	First enrolment on 20 November 2025	
References of Publications (if any)		
Type of study	Prospective observational cohort	
Main objectives	To describe the clinical burden of JEV infection in children hospitalized with febrile neurological syndrome (FNS) associated with Japanese encephalitis. To quantify the	





	- S SCIENCE
	asymptomatic circulation of Japanese encephalitis virus (JEV) among a cohort of children living in Cambodia by prospectively following non-febrile children at the time of recruitment.
Secondary objectives	<ul> <li>To estimate the anti-JEV seropositivity rate in children attending Kantha Bopha hospitals for different age groups.</li> <li>To identify the etiologies of FNS in children.</li> <li>To describe the influence of dengue immunity on the epidemiological, clinical, and biological characteristics of JEV infection (cohorts 1 and 2).</li> <li>To develop new tools (Luminex serology) for diagnosis of JEV infection</li> <li>To develop evaluate new tools (QUIASTAT) for diagnosis of meningitis and encephalitis infection in Cambodia</li> <li>To model anti-JEV antibody kinetics over time following natural infection and vaccination (cohorts 1 and 2).</li> <li>Using mathematical modeling of antibody titers, to quantify DENV and JEV interaction, e.g., to estimate the reduction of the risk of JEV infection following DENV infection.</li> </ul>
Contents	
A - Overall results	of the research
B - Secondary re-u	ase of data and samples

#### A - Overall results of the research

#### **B** - Secondary re-use of data and samples

This section concerns participants who have been included in the research and have agreed to the re-use of their data and/or samples. Through its website and this document, the research sponsor informs you of projects relating to the secondary re-use of your data and/or samples.

**B1. For the uninitiated or ongoing programmed projects listed below only**, you have the option objecting to the secondary use of your samples and/or data. To do so, please send an e-mail to **dpo@inserm.fr** giving your identity, the name of the trial and the title of the project for which you object to the re-use of your data and/or samples up to one week before the planned date of completion of the project.

Non-initiated programmed projects

Project title	
Project summary	
Provisional project completion date	
Data recipients in France	
Recipient of data abroad	





Identity and data controller	
Data and/or sample transfer	
Retention period for data and/or samples	
Data category	
Projects in progress	

Project title	
Project summary	
Project start dates	
Data recipients in France	
Recipient of data abroad	
Identity and data controller	
Data and/or sample transfer	
Retention period for data and/or samples	
Data category	

## **<u>B2.</u>** You cannot object to <u>completed projects</u>.

Completed projects

Project title	
Project summary	
Project start and end dates	
Data recipients in France	
Recipient of data abroad	
Identity and data controller	
Data and/or sample transfer	
Retention period for data and/or samples	
Data category	
Overall project results	Publication or summary of results